A Molecular Diagnostic Platform Devised from Supramolecular Gold-Oligo NanoNet Assembly for Differentiating RhD Genotypes Among Transfusion-Dependent Patients

Blood transfusion is integral to patients with blood-related disorders, necessitating point-of-care diagnosis for further treatment. Successfully differentiating Rh antigens based on their genotypes is fundamental for mitigating post-transfusion complexities. Inspired by the need for extended blood typing, we demonstrate the use of a supramolecular oligonucleotide-conjugated gold nanoassembly (Au-Oligo-net) to determine the RhD-positive and RhD-negative samples. In the presence of the RhD-positive phenotype, the Au-Oligo-net assemblies targeted toward RHD exons 5, 7, and 10 will undergo complementary binding with their respective exon sequence, where the addition of duplex-specific nuclease causes specific cleavage at the hybridized genetic segments. This results in the deagglomeration of the nanonet assembly, causing a significant shift in their plasmonic spectra. On the other hand, in the absence of the target exon, the Au-Oligo-net remains aggregated, providing a distinct difference between the two RhD phenotypes. The sensing principle has been validated using varied bioanalytical techniques, including UV-visible spectroscopy, transmission electron microscopy, small-angle neutron scattering, photoacoustic response, etc. The functional applicability of the designed platform has been substantiated using human blood specimens, which were collected from different transfusion-dependent patients of varying RhD phenotypes, who were unlikely to have any weak or partial D signature. Experimental results indicate that the sensing platform can distinguish RhD-positive samples from a limited set of RhD-negative samples, primarily those with RHD deletion, with a limit of detection (LOD) of ∼12.5 pg/μL for RhD-positive DNA. Given the current workflow requirements, this plasmonic sensing strategy should be considered as a bench-top proof-of-concept platform with future potential for simplification and potential applicability in resource-limited settings and in developing countries.

Authors

Institutions

Publication Details

Journal
ACS Applied Bio Materials
Published
2026-06-17
DOI
https://doi.org/10.1021/acsabm.5c02427
Primary Topic
Blood groups and transfusion
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Molecular Diagnostic Platform Devised from Supramolecular Gold-Oligo NanoNet Assembly for Differentiating RhD Genotypes Among Transfusion-Dependent Patients

Shyamal Karmakar, Sugam Kumar, Suvro Sankha Datta, K M Neethu et al.
ACS Applied Bio Materials
Blood groups and transfusion
article

A Molecular Diagnostic Platform Devised from Supramolecular Gold-Oligo NanoNet Assembly for Differentiating RhD Genotypes Among Transfusion-Dependent Patients

Shyamal Karmakar, Sugam Kumar, Suvro Sankha Datta, K M Neethu, Rijo Rajeev, Parikshit Moitra, Gunjan Verma, Paresh Mohanty, Debapriya Chatterjee
article en

Abstract

Blood transfusion is integral to patients with blood-related disorders, necessitating point-of-care diagnosis for further treatment. Successfully differentiating Rh antigens based on their genotypes is fundamental for mitigating post-transfusion complexities. Inspired by the need for extended blood typing, we demonstrate the use of a supramolecular oligonucleotide-conjugated gold nanoassembly (Au-Oligo-net) to determine the RhD-positive and RhD-negative samples. In the presence of the RhD-positive phenotype, the Au-Oligo-net assemblies targeted toward RHD exons 5, 7, and 10 will undergo complementary binding with their respective exon sequence, where the addition of duplex-specific nuclease causes specific cleavage at the hybridized genetic segments. This results in the deagglomeration of the nanonet assembly, causing a significant shift in their plasmonic spectra. On the other hand, in the absence of the target exon, the Au-Oligo-net remains aggregated, providing a distinct difference between the two RhD phenotypes. The sensing principle has been validated using varied bioanalytical techniques, including UV-visible spectroscopy, transmission electron microscopy, small-angle neutron scattering, photoacoustic response, etc. The functional applicability of the designed platform has been substantiated using human blood specimens, which were collected from different transfusion-dependent patients of varying RhD phenotypes, who were unlikely to have any weak or partial D signature. Experimental results indicate that the sensing platform can distinguish RhD-positive samples from a limited set of RhD-negative samples, primarily those with RHD deletion, with a limit of detection (LOD) of ∼12.5 pg/μL for RhD-positive DNA. Given the current workflow requirements, this plasmonic sensing strategy should be considered as a bench-top proof-of-concept platform with future potential for simplification and potential applicability in resource-limited settings and in developing countries.

ACS Applied Bio Materials
Bhabha Atomic Research Centre (IN), Solid State Physics Laboratory (IN), Homi Bhabha National Institute (IN), Tata Medical Center (IN), Division of Chemistry (US), Indian Institute of Science Education and Research Berhampur (IN)
Indian Council of Medical Research
Partnerships for the goals
Openalex Percentile: Top 9%
Blood groups and transfusion
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.